公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2020 | Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study | Tan D.S.-W.; Leighl N.B.; Riely G.J.; CHIH-HSIN YANG ; Sequist L.V.; Wolf J.; Seto T.; Felip E.; Aix S.P.; Jonnaert M.; Pan C.; Tan E.Y.; Ko J.; Moody S.E.; Kim D.-W. | The Lancet Respiratory Medicine | 40 | 37 | |
2016 | Safety of gefitinib in non-small cell lung cancer treatment | Hsiue E.H.-C.; JIH-HSIANG LEE ; CHIA-CHI LIN ; CHIH-HSIN YANG | Expert Opinion on Drug Safety | 19 | 15 | |
2020 | Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial | CHIH-HSIN YANG ; Camidge D.R.; Yang C.-T.; Zhou J.; Guo R.; Chiu C.-H.; Chang G.-C.; Shiah H.-S.; Chen Y.; Wang C.-C.; Berz D.; Su W.-C.; Yang N.; Wang Z.; Fang J.; Chen J.; Nikolinakos P.; Lu Y.; Pan H.; Maniam A.; Bazhenova L.; Shirai K.; Jahanzeb M.; Willis M.; Masood N.; Chowhan N.; Hsia T.-C.; Jian H.; Lu S. | Journal of Thoracic Oncology | 87 | 75 | |
2023 | Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions | Piotrowska, Zofia; Tan, Daniel Shao-Weng; Smit, Egbert F; Spira, Alexander I; Soo, Ross A; Nguyen, Danny; Lee, Victor Ho-Fun; CHIH-HSIN YANG ; Velcheti, Vamsidhar; Wrangle, John M; Socinski, Mark A; Koczywas, Marianna; Janik, John E; Jones, Jeffrey; Yu, Helena Alexandra | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 5 | 2 | |
2017 | Scientific Advances in Thoracic Oncology 2016 | Soo R.A; Stone E.C.A; Cummings K.M; Jett J.R; Field J.K; Groen H.J.M; Mulshine J.L; Yatabe Y; Bubendorf L; Dacic S; Rami-Porta R; Detterbeck F.C; Lim E; Asamura H; Donington J; Wakelee H.A; Wu Y.-L; Higgins K; Senan S; Solomon B; Kim D.-W; Johnson M; CHIH-HSIN YANG ; Sequist L.V; Shaw A.T; Ahn M.-J; Costa D.B; Patel J.D; Horn L; Gettinger S; Peters S; Wynes M.W; Faivre-Finn C; Rudin C.M; Tsao A; Baas P; Kelly R.J; Leighl N.B; Scagliotti G.V; Gandara D.R; Hirsch F.R; Spigel D.R. | Journal of Thoracic Oncology | 42 | 31 | |
2015 | Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer | BIN-CHI LIAO ; CHIA-CHI LIN ; CHIH-HSIN YANG | Current Opinion in Oncology | 122 | 109 | |
2013 | Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: An open-label single-arm study | Chang G.-C; Tsai C.-M; Hsia T.-C; CHIH-HSIN YANG ; Abdulnabi R; Blair J.M; Linn C. | Journal of the Formosan Medical Association | 1 | 1 | |
2019 | Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients | BIN-CHI LIAO ; Griesing S.; CHIH-HSIN YANG | Therapeutic Advances in Medical Oncology | 27 | 25 | |
2010 | Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer | Wu J.-Y.; JIN-YUAN SHIH ; CHIH-HSIN YANG ; KUAN-YU CHEN ; CHAO-CHI HO ; CHONG-JEN YU ; PAN-CHYR YANG | International Journal of Cancer | 53 | 45 | |
2013 | A selective ALK inhibitor in ALK-rearranged patients | CHIH-HSIN YANG | The Lancet Oncology | 7 | 5 | |
2019 | Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer | Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot D.M; Tan E.-H; Tanaka H; Wu Y.-L; CHIH-HSIN YANG ; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N. | Lung Cancer | 26 | 26 | |
2022 | Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies | Miura, Satoru; Jung, Hyun Ae; Lee, Shin Yup; Lee, Seung Hyeun; Lee, Min Ki; Lee, Yong Chul; Hochmair, Maximilian J; Yang, Cheng-Ta; Märten, Angela; CHIH-HSIN YANG ; Popat, Sanjay | OncoTargets and therapy | 6 | 5 | |
2020 | Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Final analysis of the GioTag study | Hochmair M.J.; Morabito A.; Hao D.; Yang C.-T.; Soo R.A.; CHIH-HSIN YANG ; Gucalp R.; Halmos B.; M?rten A.; Cufer T. | Future Oncology | 49 | 45 | |
2019 | Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: Updated analysis of the observational GioTag study | Hochmair M.J; Morabito A; Hao D; Yang C.-T; Soo R.A; CHIH-HSIN YANG ; Gucalp R; Halmos B; Wang L; Märten A; Cufer T. | Future Oncology | 71 | 67 | |
2018 | Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: An observational study | Hochmair M.J; Morabito A; Hao D; Yang C.-T; Soo R.A; CHIH-HSIN YANG ; Gucalp R; Halmos B; Wang L; Golembesky A; Märten A; Cufer T. | Future Oncology | 88 | 87 | |
2021 | Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC | BIN-CHI LIAO ; Hsu, Wei-Hsun; JIH-HSIANG LEE ; CHING-YAO YANG ; TZU-HSIU TSAI ; WEI-YU LIAO ; CHAO-CHI HO ; CHIA-CHI LIN ; JIN-YUAN SHIH ; CHONG-JEN YU ; Soo, Ross A; CHIH-HSIN YANG | JTO clinical and research reports | 2 | 0 | |
1994 | Severe isolated acute hepatic graft-versus-host disease with vanishing bile duct syndrome | KUN-HUEI YEH ; Hsieh H.-C.; JIH-LUH TANG ; Lin M.-T.; CHIH-HSIN YANG ; YAO-CHANG CHEN | Bone Marrow Transplantation | 21 | 11 | |
2011 | Skin manifestations of gefitinib and the association with survival of advanced non-small-cell lung cancer in Taiwan | Wang, Shiou-Han; CHIH-HSIN YANG ; HSIEN-CHING CHIU ; Hu, Fu-Chang; CHIH-CHIEH CHAN ; YI-HUA LIAO ; Chen, Hsiao-Chin; CHIA-YU CHU | Dermatologica Sinica | 3 | 3 | |
2011 | Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor | Chang T.-H.; Tsai M.-F.; KANG-YI SU ; SHANG-GIN WU ; Huang C.-P.; SUNG-LIANG YU ; Yu Y.-L.; Lan C.-C.; CHIH-HSIN YANG ; Lin S.-B.; Wu C.-P.; JIN-YUAN SHIH ; PAN-CHYR YANG | American Journal of Respiratory and Critical Care Medicine | 144 | 140 | |
2012 | Small-cell lung cancer treatment: Where is the target? | CHIH-HSIN YANG | Journal of Thoracic Oncology | 0 | 0 | |